116 related articles for article (PubMed ID: 17032519)
41. Intrauterine uterine contraception and chronic urticaria: a case series.
Wunschel J; Poole JA
Ann Allergy Asthma Immunol; 2017 Mar; 118(3):378-380. PubMed ID: 28111112
[No Abstract] [Full Text] [Related]
42. Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone.
Meaidi A; Torp-Pedersen C; Lidegaard Ø; Mørch LS
JAMA; 2023 Mar; 329(11):935-937. PubMed ID: 36943224
[TBL] [Abstract][Full Text] [Related]
43. Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer.
Neven P; Amant F; Poppe W; Van den Broecke R
Fertil Steril; 2009 Apr; 91(4):e5; author reply e6. PubMed ID: 19249759
[No Abstract] [Full Text] [Related]
44. Postpartum glucose tolerance in women with gestational diabetes using levonorgestrel intrauterine contraception.
Kiley JW; Hammond C; Niznik C; Rademaker A; Liu D; Shulman LP
Contraception; 2015 Jan; 91(1):67-70. PubMed ID: 25193535
[TBL] [Abstract][Full Text] [Related]
45. [A case report. Sepsis in connection with levonorgestrel IUD].
Ottander U; Bäckström T; Högberg U; Löfgren M
Lakartidningen; 1995 Nov; 92(48):4555-7. PubMed ID: 7490972
[No Abstract] [Full Text] [Related]
46. Sonographic findings in primary ovarian pregnancy.
Athey PA; Jayson HT; Estrada R; Watson AB
J Clin Ultrasound; 1990; 18(9):730-2. PubMed ID: 2174926
[No Abstract] [Full Text] [Related]
47. [Connection between levonorgestrel-IUD and GAS (Group A Streptococcus) sepsis? Reliable risk assessment is not yet possible].
Milsom I; Landgren BM; Alestig K
Lakartidningen; 1995 Dec; 92(50):4781-2. PubMed ID: 8538290
[No Abstract] [Full Text] [Related]
48. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
[TBL] [Abstract][Full Text] [Related]
49. Levonorgestrel-releasing intrauterine system and breast cancer; Is there an association?
Al Kiyumi MH; Al Battashi K; Al-Riyami HA
Acta Obstet Gynecol Scand; 2021 Sep; 100(9):1749. PubMed ID: 34021506
[No Abstract] [Full Text] [Related]
50. Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding.
Nelson AL
Womens Health (Lond); 2010 May; 6(3):347-56. PubMed ID: 20426599
[TBL] [Abstract][Full Text] [Related]
51. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.
Mansour D
Contraception; 2012 Mar; 85(3):224-34. PubMed ID: 22067761
[TBL] [Abstract][Full Text] [Related]
52. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
Selim MF; Hussein AF
Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
[TBL] [Abstract][Full Text] [Related]
53. Guidelines for the use of long-acting reversible contraceptives.
Randel A
Am Fam Physician; 2012 Feb; 85(4):403-4. PubMed ID: 22335322
[No Abstract] [Full Text] [Related]
54. Algorithm for nonvisible strings of levonorgestrel intrauterine system.
Vilos GA; Di Cecco R; Marks J
J Minim Invasive Gynecol; 2010; 17(6):805-6. PubMed ID: 20955995
[TBL] [Abstract][Full Text] [Related]
55. Transmural migration and perforation of a levonorgestrel intrauterine system: a case report and review of the literature.
Ferguson CA; Costescu D; Jamieson MA; Jong L
Contraception; 2016 Jan; 93(1):81-6. PubMed ID: 26386445
[TBL] [Abstract][Full Text] [Related]
56. The levonorgestrel intrauterine system in nulliparous women.
Prager S; Darney PD
Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
[TBL] [Abstract][Full Text] [Related]
57. Hair loss with use of the levonorgestrel intrauterine device.
Paterson H; Clifton J; Miller D; Ashton J; Harrison-Woolrych M
Contraception; 2007 Oct; 76(4):306-9. PubMed ID: 17900442
[TBL] [Abstract][Full Text] [Related]
58. Are two intrauterine contraceptive devices better than one?
Granberg S
Ultrasound Obstet Gynecol; 2014 Jul; 44(1):121. PubMed ID: 24861768
[No Abstract] [Full Text] [Related]
59. Clinical inquiry: what are the benefits and risks of IUDs in adolescents?
Shih EM; Zolotor AJ; Firnhaber GC
J Fam Pract; 2012 Nov; 61(11):695-6. PubMed ID: 23256103
[TBL] [Abstract][Full Text] [Related]
60. Intrauterine contraception for adolescents aged 14-18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T 380A.
Godfrey EM; Memmel LM; Neustadt A; Shah M; Nicosia A; Moorthie M; Gilliam M
Contraception; 2010 Feb; 81(2):123-7. PubMed ID: 20103449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
